Clinical trial Recruiting at 1 site Interventional Ages 21 and up

Vibrant capsule treatment for neurogenic bowel in spinal cord injury

Official title: Pilot Trial of the Vibrant Capsule for Spinal Cord Injury Neurogenic Bowel Dysfunction

Run by The University of Texas Health Science Center, Houston · NCT07213986 · Data updated 2026-11-12

This trial will test whether taking the Vibrant capsule is safe and helps bowel control in people with chronic spinal cord injury who have upper motor neuron neurogenic bowel.

More Spinal Cord Injury trials

Quick facts

Study typeInterventional
Ages21 Years and up
SexAll
Enrollment12 (estimated)
SponsorThe University of Texas Health Science Center, Houston
Academic / other
Locations1 site (Houston, Texas)
StatusRecruiting
StartedJanuary 6, 2026
Main results expectedAugust 19, 2026
Study endsAugust 19, 2026
Registry record updatedAugust 21, 2026
Trial IDNCT07213986 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with chronic (over one year) spinal cord injury causing upper motor neuron neurogenic bowel, stable neurologic function for at least six months, on a consistent bowel program for three months, having at least one bowel movement every three days, and able to communicate in English and attend the Houston site are ideal candidates.

Probably not a fit

People with frequent bowel incontinence (more than once per week), known bowel obstruction or significant GI disease, recent bowel surgery, persistent autonomic dysreflexia triggered by bowel care, pregnancy, or swallowing/esophageal disorders are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-site interventional study gives the Vibrant capsule to adults with chronic spinal cord injury (SCI)–related upper motor neuron neurogenic bowel to measure safety and bowel outcomes. The Vibrant capsule is already FDA-approved for chronic idiopathic constipation, and this study applies that medication to the SCI population to see if similar benefits occur. Eligible participants have had SCI for more than one year, stable neurologic function for at least six months, and an unchanged bowel program for at least three months; key exclusions include frequent bowel incontinence, certain gastrointestinal disorders, recent GI surgery, or conditions affecting swallowing. Investigators will record bowel frequency, use of bowel interventions (digital stimulation, suppositories, enemas), adverse events, and any changes in bowel-management needs over the study period.

Why it matters

Potential benefit: If successful, the Vibrant capsule could reduce constipation symptoms and lower the need for manual stimulation, suppositories, or enemas for people with SCI-related neurogenic bowel.

How similar studies have gone: The Vibrant capsule has shown benefit and is FDA-approved for chronic idiopathic constipation, but its use specifically for SCI-related neurogenic bowel is novel and has limited prior data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Individuals with chronic spinal cord injury (SCI) of more than one year.
* Stable neurological level and function of SCI for at least six months.
* Consistent bowel program without changes for at least 3 months.
* At least one scheduled bowel movement (BM) every three days.
* Use of digital stimulation, suppositories, enemas, or mini enemas, as part of the scheduled bowel program.
* Use of oral medications as part of the bowel program.

Exclusion Criteria:

* Bowel incontinence occurring more than once per week.
* Non-English-speaking individuals.
* History of bowel obstruction, ileus, diverticulitis, or bowel surgery for a disease (appendix removal is ok).
* Persistent autonomic dysreflexia (AD) triggered by bowel movements.
* Recent changes to spasticity medications within the past month.
* History of significant gastrointestinal disorders
* History of Zenker's diverticulum
* Dysphagia
* Esophageal stricture
* Eosinophilic esophagitis or achalasia
* Pregnancy.
* Presence of implanted devices that could be affected by proximity to a direct current magnetic field.

Where it's running

  • TIRR Memorial Hermann
    Houston, Texas, United States
    Recruiting

Study contacts

  • Principal investigator: Argyrios Stampas, MD — The University of Texas Health Science Center, Houston
  • Study coordinator: Argyrios Stampas, MD
  • Email: argyrios.stampas@uth.tmc.edu
  • Phone: 7127975938

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.